LIGABUE, Alessio
 Distribuzione geografica
Continente #
NA - Nord America 1.536
EU - Europa 681
AS - Asia 115
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
AF - Africa 1
Totale 2.337
Nazione #
US - Stati Uniti d'America 1.530
GB - Regno Unito 254
DE - Germania 88
SE - Svezia 72
FR - Francia 65
PL - Polonia 64
CN - Cina 51
IT - Italia 46
UA - Ucraina 35
HK - Hong Kong 23
FI - Finlandia 20
TR - Turchia 14
BG - Bulgaria 13
SG - Singapore 12
RU - Federazione Russa 9
BE - Belgio 8
CA - Canada 6
IE - Irlanda 5
IN - India 4
IR - Iran 4
VN - Vietnam 4
MY - Malesia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AU - Australia 1
EU - Europa 1
JP - Giappone 1
LT - Lituania 1
NZ - Nuova Zelanda 1
RO - Romania 1
TZ - Tanzania 1
Totale 2.337
Città #
Fairfield 246
Southend 211
Woodbridge 150
Ashburn 139
Chandler 138
Houston 105
Cambridge 86
Ann Arbor 83
Seattle 83
Wilmington 79
Jacksonville 68
Kraków 64
Nyköping 52
Dearborn 48
Frankfurt am Main 40
Modena 32
Hong Kong 23
Fremont 18
New York 18
San Diego 18
Beijing 15
Princeton 14
Grafing 13
Sofia 13
Eugene 12
Helsinki 9
Des Moines 8
San Mateo 8
Brussels 7
London 7
Redwood City 7
Izmir 6
Shanghai 6
Boardman 5
Dublin 5
Toronto 5
Bremen 4
Dong Ket 4
Falls Church 4
Detroit 3
Hefei 3
Los Angeles 3
Norwalk 3
Phoenix 3
Saint Petersburg 3
Auburn Hills 2
Casagiove 2
Hounslow 2
Indiana 2
Kilburn 2
Milan 2
Monmouth Junction 2
Nanjing 2
Ardabil 1
Auckland 1
Augusta 1
Baotou 1
Borås 1
Chiswick 1
Clearwater 1
Dar es Salaam 1
Dongguan 1
Filottrano 1
Hangzhou 1
Hanover 1
Harbin 1
Irving 1
Kish 1
Kunming 1
Louvain 1
Misterbianco 1
Mountain View 1
Nanchang 1
Nürnberg 1
Ottawa 1
Parma 1
Sacramento 1
Serra 1
Shiraz 1
Southwark 1
Taiyuan 1
Tokyo 1
Verona 1
Totale 1.917
Nome #
Protein–protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase 275
Distamycin A and derivatives as synergic drugs in cisplatin-sensitive and -resistant ovarian cancer cells. 226
Spermidine/spermine N1-acetyltransferase transient over-expression restores sensitivity of resistant human ovarian cancer cells to N1,N12-bis(ethyl)spermine and to cisplatin 218
Translational repression of thymidylate synthase by targeting its mRNA 218
Characterization of the cell growth inhibitory effects of a novel DNA-intercalating bipyridyl-thiourea-Pt(II) complex in cisplatin-sensitive and-resistant human ovarian cancer cells 210
Spermidine/spermine N1-acetyltranferasemodulation by novel folate cycle inhibitors in cisplatin-sensitive and -resistanthuman ovarian cancer cell lines 207
Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells 192
Ligand-Based Virtual Screening and ADME-Tox Guided Approach to Identify Triazolo-quinoxalines as Folate Cycle Inhibitors. 172
Transcriptional activation and cell cycle block are the keys for 5-fluorouracil induced up-regulation of human thymidylate synthase expression 162
Studies on the anti-proliferative effects of novel DNA-intercalating bipyridyl-thiourea-Pt(II) complexes against cisplatin-sensitive and -resistant human ovarian cancer cells 151
Collateral sensitivity to novel folate cycle inhibitors enhances cisplatin effectiveness against human ovarian cancer cells. 129
SSAT modulation by putative regulators of folate cycle enzymes expression in cisplatin-sensitive and –resistant human ovarian cancer cell lines. 114
Erratum: Protein-protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase (Proceedings of the National Academy of Sciences of the United States of America (2011) 108, 34 (E542-E549) DOI: 10.1073/pnas.1104829108) 96
Totale 2.370
Categoria #
all - tutte 9.328
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.328


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019134 0 0 0 0 0 0 0 0 0 0 86 48
2019/2020528 45 22 20 50 70 62 78 59 55 17 20 30
2020/2021458 37 22 48 55 51 34 22 59 14 63 29 24
2021/2022304 8 27 31 5 17 34 14 8 32 22 66 40
2022/2023305 31 44 22 41 34 48 2 37 32 1 5 8
2023/2024183 4 10 14 11 79 31 10 13 0 3 8 0
Totale 2.370